Article Data

  • Views 521
  • Dowloads 160

Original Research

Open Access

Risk assessment for ovarian cancer

  • B. Pięta1,*,
  • K. Chmaj-Wierzchowska1

1Department of Maternal and Child Health, Poznan University of Medical Sciences, Poznań, Poland

DOI: 10.12892/ejgo3772.2018 Vol.39,Issue 4,August 2018 pp.517-523

Published: 10 August 2018

*Corresponding Author(s): B. Pięta E-mail: bpieta@gpsk.am.poznan.pl

Abstract

Introduction: Ovarian cancer (OC) is the most common malignancy among women and epidemiological data report the trends in OC incidence to steadily increase. Objectives: The aim of the study was to analyze selected, non-genetic risk factors for OC, and to design a mathematical model and a risk assessment tool for it. Materials and Methods: The study included healthy women with no focal changes in the breast and ovaries (control group) and patients with OC (study group). A total of 1346 women, aged from 18 to 80, were included in the study. An original questionnaire, designed especially for the purpose of the study and comprising of 40 questions, was used as one of the evaluation tools. All respondents underwent a clinical psychological evaluation. Results: Risk Assessment for Ovarian Cancer Chart (RAFOCC) was designed on the basis of the odds ratio (OR) analysis for individual parameters and revealed that women who scored >31.5 points on a scale from 0 to 72, with a 72% test sensitivity (95% confidence interval (CI) 0.656-0.783) and 75% specificity (95% CI 0.718-0.770), face a statistically significantly increased risk for OC. Conclusions: RAFOCC is a useful screening tool for identifying women with increased risk for OC. Women who scored >31.5 points face a statistically significantly increased risk for OC. High-risk patients should be offered timely medical care and undergo further diagnostic testing.

Keywords

Ovarian cancer; Risk assessment; RAFOCC.

Cite and Share

B. Pięta,K. Chmaj-Wierzchowska. Risk assessment for ovarian cancer. European Journal of Gynaecological Oncology. 2018. 39(4);517-523.

References

[1] Nowak-Markwitz E., Spaczyński M.: “Ovarian cancer – modern approach to its origin and histogenesis”. Gin. Pol. 2012, 83, 454.

[2] Bray F., Loos AH., Tognazzo S., La Vecchia C.: “Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000”. Int. J. Cancer, 2005, 113, 997

[3] Pięta B., Grodecka-Gazdecka S., Chmaj-Wierzchowska K., Kramer L., Opala T.: “Analysis of the odds ratio for developing breast cancer in women”. Gin. Pol., 2011, 82, 755.

[4] Gromadzka A., Kubiczak M., Jankowska A.: “Gene therapy applications in gynecologic malinances management”. Ginekol. Pol., 2010, 81, 50-54

[5] Smoleń A., Stachowicz N., Czekierowski A., Kotarski J.: “The estimation of the probability of tumor malignacy on the basis of test combination in the primary diagnosis of adnexal tumors”. Ginekol. Pol., 2010, 81, 254.

[6] Bednarek W., Mazurek M., Ćwiklińska A., Barczyński B.: “Expression of select angiogenesis markers and modulators in pre-, peri-, and postmenopausal women with ovarian cancer”. Ginekol. Pol., 2009, 80, 88.

[7] Pięta B., Chmaj-Wierzchowska K., Opala T.: “Life style and risc of development of breast and ovarian cancer”. AAEM., 2012, 19, 379.

[8] Pięta B., Chmaj-Wierzchowska K., Opala T.: “Past obstetric history and risc of ovarian cancer”. AAEM., 2012, 19, 385.

[9] Beehler G.P., Sekhon M., Baker J.A., Teter B.E., McCann S.E., Rodabaugh K.J., Moysich K.B.: ‘Risk of ovarian cancer associated with BMI varies by menopausal status”. J. Nutr. 2006, 136, 2881.

[10] Zatoński W.: “European Code of Fight against cancer”. 2003

[11] Kaleta-Stasiołek D., Szmigielska K., Jegier A.: “Physical activity in selected cancers prevention”. Pol. Arch. Med. Wewn. 2003, 6, 661.

[12] Pukkala E., Poskiparta M., Apter D., Vihko V.: “Life-long physical activity and cancer risk among Finnish female teachers”. Eur. J. Cancer. Prev., 1993, 2, 369.

[13] Dorgan J.F., Brown C., Barrett M, Splansky G.L., Kreger B.E., D’Agostino R.B., et al.: “Physical activity and risk of breast cancer in the Framingham heart study”. Am. J. Epidemiol., 1994, 139, 662.

[14] Verloop J., Rookus M.A., van der Kooy K., Van Leeuwen F.E.: “Physical activity and breast cancer risk in women aged 20-54 years”. J. Natl. Cancer Inst., 2000, 92, 128.

[15] Zadrożny M.: “Treatment of malignant and benign diseases of breast”. In: Pertyński T. (ed). Diagnostics and therapy of the age of menopause. Wrocław: Urban&Partner, 2004.

[16] Gabryś M.St., Popiela A., Popiela M., Mazur R.: “Ovarian cancer in the aspect of oncological profilaxis”. Polska Medycyna Rodzinna, 2004, 6, 837.

[17] Markowska A.: “Review of theories on development of ovarian cancer. Leptin as a potential agent engaged in carcinogenesis”. J. Oncol., 2007, 57, 518.

[18] Franceschi S., La Vecchia C., Booth M., Tzonou A., Negri E., Parazzini F., et al.: “Pooled analysis of 3 European case-control studies of ovarian cancer: II. Age at menarche and menopause”. Int. J. Cancer, 1991, 19, 57.

[19] Parazzini F., Chatenoud L., Chiantera V. Benzi G, Surace M, La Vecchia C.: “Population attributable risk for ovarian cancer”. Eur. J. Cancer, 2000, 36, 520.

[20] Kutarska E.: “Ovarian cancer – ways to improve curability”. Onkologiai Radioterapia, 2007, 1, 26.

[21] Bulsa M., Czaja-Bulsa G.: “Ovarian cancer prevention”. Family Medicine&Primary Care Review, 2006, 8, 375.

[22] Schlesselman J.J.: “Net effect of oral contraceptive use on the risk of cancer in women in the United States”. Obstet. Gynecol., 1995, 85, 793.

[23] Vessey M.: “Mortality in relation to oral contraceptive use and cigarette smoking”. Lancet, 2003, 362, 185.

[24] Rodriguez C., Callae E.E., Coates R.J.: “Estrogen replacement therapy and fatal ovarian”. Am. J. Epidemiol., 1995, 141, 828.

[25] Michalak J., Godlewski D., Grodecka-Gazdecka S.: “Methodology of breast cancer screening”. Przegląd Położniczo-Ginekologiczny, 2003, 3, 231.

[26] Park Y., Lee J.H., Hong D.J., Lee E.Y., Kim H.S.: “Diagnostic performances of HE4 and Ca125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases”. Clin. Biochem., 2011, 44, 884.

[27] Paek J., Lee S.H., Yim G.W., Lee M., Kim Y.J., Nam E.J., et al.: “Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2011, 158, 338.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top